Valuation: Catalyst Pharmaceuticals, Inc.

Market Cap 3.85B 3.37B 3.11B 2.87B 5.45B 367B 5.54B 37.14B 14.58B 181B 14.47B 14.15B 622B P/E 2026 *
16.1x
P/E 2027 * 13.1x
Enterprise Value 3.85B 3.37B 3.11B 2.87B 5.45B 367B 5.54B 37.14B 14.58B 181B 14.47B 14.15B 622B EV / Sales 2026 *
6.06x
EV / Sales 2027 * 5.37x
Free-Float
94.43%
Yield 2026 *
-
Yield 2027 * -
1 day-0.37%
1 week-0.37%
Current month-0.37%
1 month+0.74%
3 months+25.46%
6 months+40.49%
Current year+34.03%
1 week 27.1
Extreme 27.1
27.2
1 month 26.6
Extreme 26.6
27.4
Current year 18.96
Extreme 18.965
27.4
1 year 16.15
Extreme 16.15
27.4
3 years 10.93
Extreme 10.93
27.4
5 years 4.12
Extreme 4.12
27.4
10 years 0.62
Extreme 0.621
27.4
Manager TitleAgeSince
Chief Executive Officer 65 31/12/2023
Director of Finance/CFO 55 31/12/2023
Chief Tech/Sci/R&D Officer 62 31/05/2025
Director TitleAgeSince
Chairman 78 31/12/2001
Director/Board Member 62 30/09/2002
Director/Board Member 65 18/02/2015
Change 5-day change 1-year change 3-year change Capi.($)
-0.37%-0.37% - - 3.85B
-0.51%+1.57%+17.05%-7.30% 67.61B
-5.16%-8.63%+38.70%+203.59% 51.6B
+5.28%+39.50%+39.50%+39.50% 43B
-2.10%+0.89%-48.99%-53.63% 40.94B
+0.12%-7.85%+48.39%-28.83% 29.4B
-10.83%-14.41%+102.94%-44.10% 27.09B
-1.53%-0.13%+70.16%+85.73% 23.32B
+3.88%+2.16%+11.36%+192.66% 19.89B
-1.59%-1.63%+64.87%+130.98% 16.91B
Average -1.28%-3.02%+38.22%+57.62% 35.53B
Weighted average by Cap. -1.35%-2.83%+31.31%+48.53%

Financials

2026 *2027 *
Net sales 636M 556M 513M 474M 900M 60.68B 915M 6.13B 2.41B 29.89B 2.39B 2.34B 103B 718M 628M 579M 535M 1.02B 68.47B 1.03B 6.92B 2.72B 33.73B 2.7B 2.64B 116B
Net income 231M 202M 186M 172M 327M 22.04B 332M 2.23B 875M 10.86B 868M 849M 37.33B 316M 277M 255M 236M 447M 30.16B 455M 3.05B 1.2B 14.86B 1.19B 1.16B 51.08B
Net Debt - -
Logo Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Employees
182
Date Price Change Volume
10/07/26 €27.10 -0.37% 0
09/07/26 €27.20 0.00% 0
08/07/26 €27.20 0.00% 0
07/07/26 €27.20 0.00% 0
06/07/26 €27.20 0.00% 0
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
31.47USD
Average target price
31.67USD
Spread / Average Target
+0.62%

Quarterly revenue - Rate of surprise